本文へスキップ

相互作用

Certolizumab pegol + Ciltacabtagene autoleucel

重症度: 重大

Certolizumab pegol and Ciltacabtagene autoleucel: major interaction.

最終更新日

医療従事者向け・参照専用。このページは簡潔な要約であり、医学的助言ではなく、公式の添付文書や臨床判断に代わるものではありません。処方・調剤の前に必ず確認してください。

このページの臨床コンテンツは英語でのみ提供されています。

概要

Certolizumab pegol blocks TNF and causes immunosuppression, while ciltacabtagene autoleucel is given after lymphodepleting chemotherapy and causes prolonged cytopenias and hypogammaglobulinemia. Together they may raise the risk of serious infection. TNF inhibition may also interfere with CAR-T expansion and cytokine biology.

この相互作用をわかりやすく説明すると

Certolizumab pegol and Ciltacabtagene autoleucel can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for.

Certolizumab pegol belongs to Musculoskeletal; Ciltacabtagene autoleucel belongs to Miscellaneous.

エビデンスレベル: Low

なぜ起こるのか

Additive immunosuppression from TNF blockade and CAR-T related lymphodepletion and cytopenias.

対処法

Avoid starting certolizumab pegol around CAR-T infusion unless clearly needed, and consider an alternative. If it cannot be avoided, monitor closely for infection and cytopenias.

薬剤師に尋ねること

  • Does the benefit of taking both outweigh the risk in my case?
  • Do I need any blood test, ECG or other check while on both?
  • What early warning signs should I watch for, and what should I do if they appear?

Bring a full list of your medicines, including over-the-counter products, supplements and herbal remedies, to every pharmacy visit.

Pro+会員向け

ページ全体を見る

アカウントを作成してPro+トライアルを始めると、Certolizumab pegolとCiltacabtagene autoleucelの臨床対応の詳細なアドバイス、追加の注記、エビデンスの詳細、処方全体を対象とした相互作用チェッカーを利用できます。

  • Full clinical management advice
  • Additional notes
  • Evidence detail
  • Interaction checker for a whole prescription

WebでPro+を14日間無料でお試し。カード登録不要。

よくある質問

Can I take Certolizumab pegol with Ciltacabtagene autoleucel?

MediHelp rates the interaction as major. Certolizumab pegol and Ciltacabtagene autoleucel can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for. Certolizumab pegol blocks TNF and causes immunosuppression, while ciltacabtagene autoleucel is given after lymphodepleting chemotherapy and causes prolonged cytopenias and hypogammaglobulinemia. Together they may raise the risk of serious infection. TNF inhibition may also interfere with CAR-T expansion and cytokine biology.

How serious is the interaction between Certolizumab pegol and Ciltacabtagene autoleucel?

MediHelp rates it major, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Avoid starting certolizumab pegol around CAR-T infusion unless clearly needed, and consider an alternative. If it cannot be avoided, monitor closely for infection and cytopenias.

What other medicines interact with Certolizumab pegol?

MediHelp also lists interactions of Certolizumab pegol with, for example, Adenovirus types 4 and 7 live, Bcg intravesical live, Bcg vaccine live. The full list is on the Certolizumab pegol page.

完全なモノグラフ、用量、相互作用チェッカーはMediHelpアプリで

MediHelpアプリで、完全なリファレンスを開き、複数薬剤の相互作用をチェックし、用量ツールを利用できます。

A–Zで探す · 相互作用

アプリを入手 ログイン